Phthalates in Drugs and Male Genital Malformation

药物中的邻苯二甲酸盐与男性生殖器畸形

• 批准号: 7737225
• 负责人: Sonia Hernandez-Diaz
• 金额: $ 52.1万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7737225
• 关键词: Affect; Age; Area; Attention; Behavioral; Biological Availability; Birth; Blinded; Boston; Caring; Case Study; Chemicals; Classification; Confidence Intervals; Congenital Abnormality; Cryptorchidism; Data; Defect; Development; Dibutyl Phthalate; Didanosine; Diet; Diethylhexyl Phthalate; Dose; Drug usage; Ecology; Ejaculation; Endocrine Disruptors; Enteral; Environment; Environmental Health; Epidemiologic Studies; Epidemiology; Esthetics; Exposure to; Fetus; Folate; General Population; Genital system; Genitourinary system; Goals; Gold; Hospitals; Human; Hypospadias; Infant; Infection; Infertility; Inhalators; Interest Group; Interview; Iowa; Knowledge; Laboratory Animals; Large Intestine; Lead; Male Genital Organs; Malignant neoplasm of testis; Manufacturer Name; Massachusetts; Maternal Exposure; Medical; Mesalamine; Molecular Weight; Morbidity - disease rate; Mothers; National Health and Nutrition Examination Survey; Natural experiment; New York; Non-Prescription Drugs; North America; Nurses; Observational Study; Occupations; Odds Ratio; Omeprazole; Operative Surgical Procedures; Oral; Patients; Perinatal Exposure; Pharmaceutical Preparations; Pharmacoepidemiology; Pharmacology; Philadelphia; Play; Population; Positioning Attribute; Pregnancy; Pregnant Women; Provider; Public Health; Random Allocation; Randomized; Randomized Clinical Trials; Randomized Controlled Clinical Trials; Rattus; Registries; Reporting; Research Infrastructure; Risk; Rodent; Role; Sampling; Savings; Seminal fluid; Smoke; Societies; Source; Study Subject; Surface; Surveillance Program; Syndrome; System; Teratology; Theophylline; Time; Toxic effect; Toxicology; Ulcerative Colitis; Urethra; Urinary system; Woman; administrative database; authority; case control; child bearing; consumer product; diethylphthalate; environmental agent; estrogenic activity; experience; exposed human population; human data; male; malformation; metropolitan; monobutyl phthalate; mortality; penis; phthalates; prenatal exposure; psychologic; public health relevance; reproductive; research study; urinary; urologic; xenoestrogen

DESCRIPTION (provided by applicant): Recently, there has been an enormous increase in both scientific and public concern about the potential reproductive toxicity of phthalates, a group of synthetic chemicals with a wide spectrum of industrial and consumer product applications. However, it is not widely appreciated that manufacturers use low molecular weight phthalates (e.g., diethyl phthalate [DEP] and di-n-butyl phthalate [DBP]) to make coatings for oral medications; phthalates are used to target medication release (e.g., to the large bowel) or to provide timed release. Other phthalates, such as di(2-ethylhexyl) phthalate (DEHP), may also be used in medication delivery systems, such as inhalers. Prenatal exposure of male rats to DBP and DEHP has been shown to produce cryptorchidism and hypospadias, presumably due to their anti-androgenic activity. The potential effects of prenatal exposure on the developing human fetus are not yet known. However, the presence of phthalates in some medications may contribute appreciably to human exposure, at levels well above background general population exposure level. This situation raises serious concern. We therefore propose to evaluate the risks of male genital malformations after maternal exposure to specific types of phthalates contained in medications as "inactive" ingredients. These goals can be efficiently achieved by taking advantage of data available through a large ongoing multicenter case-control surveillance program of birth defects, the Slone Epidemiology Center Birth Defects Study (BDS). Since its inception in 1976, the BDS has involved over 100 birth and tertiary hospitals in the greater metropolitan areas of Boston, Philadelphia, Toronto, San Diego, and selected regions in Iowa, as well as birth defects registries in Massachusetts and New York State. The BDS identifies infants with a wide range of malformations and a sample of non-malformed infants within five months after birth, and study nurses interview mothers within six months of delivery about demographic, behavioral, reproductive, and medical factors; and details about use of a wide range of medications, including all prescription and over-the- counter drugs. We propose to enhance accrual of the case groups of interest and compare data for more than 1,100 infants with hypospadias and 675 with cryptorchidism with data on control infants without malformations. We will calculate odds ratios and 95% confidence intervals related to in utero exposure to medications containing phthalates. The setting in which phthalate exposure occurs presents a unique opportunity: Phthalates are often included in some, but not all, drugs used for a given indication, a situation that mimics random allocation; further, like other inactive ingredients, the presence of phthalates is unlikely to be known to either prescribers or study subjects, so they are functionally blinded to exposure. Thus, the proposed observational study in some ways mimics a randomized trial by minimizing both confounding by indication and recall bias. Findings from this effort will help determine the role played by these exposures in the development of male genital malformations, and will assist public health authorities in advising women about their risks. PUBLIC HEALTH RELEVANCE: Ingredients in medications that are assumed to be "inactive" might be a major source of exposure to phthalates, a group of synthetic chemicals with widespread use in our society. These agents cause male genital malformations in laboratory animals, but we don't know their effects in humans. We will identify medications taken in pregnancy that include phthalates and determine whether these "inactive" ingredients are associated with an increased risk of two birth defects that uniquely affect male infants (hypospadias and cryptorchidism).

描述（由申请人提供）：最近，科学和公众对邻苯二甲酸盐潜在生殖毒性的关注大幅增加，邻苯二甲酸盐是一组广泛应用于工业和消费品的合成化学品。然而，制造商使用低分子量邻苯二甲酸盐（例如，邻苯二甲酸二乙酯[DEP]和邻苯二甲酸二丁酯[DBP]）来制造口服药物涂层的做法并未得到广泛认可；邻苯二甲酸盐用于靶向药物释放（例如，到大肠）或提供定时释放。其他邻苯二甲酸酯，如邻苯二甲酸二（2-乙基己基）酯（DEHP），也可用于药物输送系统，如吸入器。产前暴露于DBP和DEHP的雄性大鼠已被证明会产生隐睾和尿道下裂，可能是由于它们的抗雄激素活性。产前暴露对发育中的人类胎儿的潜在影响尚不清楚。然而，某些药物中邻苯二甲酸盐的存在可能对人类暴露有明显的贡献，其水平远高于一般人群的背景暴露水平。这种情况令人严重关切。因此，我们建议评估母亲接触药物中含有的特定类型的邻苯二甲酸盐作为“非活性”成分后男性生殖器畸形的风险。通过利用正在进行的大型多中心出生缺陷病例对照监测项目——斯隆流行病学中心出生缺陷研究（BDS）所提供的数据，可以有效地实现这些目标。自1976年成立以来，BDS已涉及波士顿、费城、多伦多、圣地亚哥等大都市地区和爱荷华州某些地区的100多家出生和三级医院，以及马萨诸塞州和纽约州的出生缺陷登记处。BDS在出生后5个月内确定了各种畸形婴儿和非畸形婴儿样本，并研究护士在分娩后6个月内对母亲进行了人口、行为、生殖和医疗因素的访谈；以及关于各种药物使用的详细信息，包括所有处方药和非处方药。我们建议加强感兴趣的病例组的累积，并将1100多名尿道下裂婴儿和675名隐睾婴儿的数据与没有畸形的对照组婴儿的数据进行比较。我们将计算子宫内接触含有邻苯二甲酸酯的药物的比值比和95%置信区间。邻苯二甲酸盐暴露的环境提供了一个独特的机会：邻苯二甲酸盐通常包含在某些（但不是全部）用于特定适应症的药物中，这种情况类似于随机分配；此外，像其他非活性成分一样，邻苯二甲酸盐的存在不太可能被处方医生或研究对象所知，因此他们对暴露是功能性盲的。因此，拟议的观察性研究在某些方面模仿了随机试验，最大限度地减少了指征和回忆偏倚的混淆。这项工作的结果将有助于确定这些接触在男性生殖器畸形的发展中所起的作用，并将协助公共卫生当局向妇女提供有关其风险的建议。公共卫生相关性：药物中被认为是“无活性”的成分可能是邻苯二甲酸盐暴露的主要来源，邻苯二甲酸盐是一组在我们社会中广泛使用的合成化学物质。这些